Metabolized to quinaprilat, the active metabolite. Significantly bound to plasma proteins.
Food reduces absorption.
Also appears to improve endothelial function, an early marker of coronary atherosclerosis. Adjunct with a diuretic or digitalis to treat CHF in those not responding adequately to diuretics or digitalis. Safety and effectiveness have not been determined in children. Geriatric clients may be more sensitive to the effects of quinapril and manifest higher peak quinaprilat blood levels. Somnolence, vertigo, insomnia, sleep disturbances, paresthesias, nervousness, depression, headache, dizziness, fatigue.